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We report here a case of a patient with anti-α-enolase 
antibodies-positive Behçet’s disease (BD), which was 
reactivated as a pathergy reaction after carbon dioxide 
laser therapy. 
CASE REPORT
A 60-year-old woman presented with multiple encrusted, 
 ery thematous ulcerations on her face. Her medical history was 
significant for BD, including recurrent oral ulceration, eryt-
hema nodosum- and Sweet’s syndrome-like skin lesions, and 
a positive pathergy test (1). Pathergy testing was performed 
by the intra cutaneous injection of 0.1 ml isotonic salt solution 
using a 20-gauge needle on the patient’s volar forearm, with 
pustule formation observed within 48 h at the injection site. 
Screening for genital ulceration and ocular involvement, such 
as iritis and uveitis, was performed; however, active disease 
involvement was not observed. The patient had been treated 
with colchicine and had been maintained in an inactive disease 
state for over a year. 
One week prior to presentation, the patient underwent carbon 
dioxide laser treatment for multiple seborrhoeic keratoses and 
lentigines at an outside clinic. However, 3 days after the procedu-
re all of the treated sites became inflamed and ulcerated (Fig. 1a). 
In addition, multiple oral ulcerations, as well as several erythema 
nodosum-like erythematous tender nodules and a blister on the 
forearm and dorsum of hand were evident (Fig. 1b). The patient 
was afebrile, and laboratory blood tests revealed leukocytosis 
of 10,030/μl with neutrophilia (80.8%), elevated ery throcyte 
sedimentation rate of 40 mm/h, and positive C-reactive protein 
of 9.480 mg/dl (normal range 0–8 mg/l). Bacterial cultures of 
the ulcerated wounds were negative. Skin lesions were biopsied, 
and histology revealed septal infiltration of lymphohistiocytes 
and neutrophils with vasculitis, consistent with the findings of 
erythema nodosum (Fig. 2a, b).
After obtaining informed consent, we collected serum samples 
from the patient, which were stored at –70˚C. The anti-α-enolase 
antibody test was performed according to the method described in 
a previous report (2). In an enzyme-linked immunosorbent assay 
(ELISA) for the anti-α-enolase antibody, the mean optical density 
(OD) (± 1 SD) for serum samples from 23 healthy controls was 
0.139 ± 0.0682 (2). An OD exceeding this value by ≥ 3 SD was 
defined as positive reactivity. The patient’s sample was positive, 
with an OD of 0.6485. Immunohistochemical analysis of a biopsy 
specimen was also performed using a rabbit anti-human α-enolase 
antibody (Acris Antibodies, Acris Antibodies GmbH, Herford, Ger-
many) in accordance with a previous report (3). The cytoplasm from 
lymphohistiocytes, neutrophils and endothelial cells were stained 
brown, whereas cell nuclei were counterstained blue (Fig. 2c, d). 
The patient was treated with systemic low-dose prednisolone 
and colchicine. One month following this treatment, skin le-
sions on both the face and forearm demonstrated improvement, 
leaving residual post-inflammatory hyperpigmentation and 
prominent depressed scars, without any evidence of recurrence 
over a 3-month follow-up period.
DISCUSSION
BD is a chronic, relapsing, multi-system vasculitis. 
The diagnosis relies on the presence of recurrent oral 
ulceration plus any two of the following: recurrent 
genital ulceration, characteristic ocular lesions, typical 
cutaneous lesions, or a positive pathergy test. 
While the pathergy reaction, defined as an induction 
of an inflammatory process following skin trauma, is not 
a pathognomonic sign, it is a typical feature of BD (4). 
Aside from its association with BD, the pathergy reac-
tion can also occur in patients with several conditions, 
including pyoderma gangrenosum, rheumatoid arthritis, 
Crohn’s disease, genital herpes and Sweet’s syndrome 
(1, 5, 6). A hypersensitivity reaction following trauma 
has also been reported in patients with BD, including 
long-lasting severe erythema and induration at the 
surgically-incised site, as well as acute exacerbations 
of arthritis following synovial biopsies (7, 8). In the 
present case, we conclude that the extensive carbon 
dioxide laser treatment induced a pathergy reaction, 
which consequently resulted in the activation of BD 
symptoms. According to a recent report, argon laser 
photocoagulation can induce skin hyper-reactivity in 
patients with BD (9).
Melikoglu et al. (10) reported that following a needle 
prick, patients with BD displayed increased influxes 
of cellular components, such as mature dendritic cells, 
monocytes, and lymphocytes, and increased expres-
sion of cytokines, including interferon (INF)-γ, inter-
leukin (IL)-12 p40, and IL-15, chemokines, such as 
macrophage inflammatory protein-3α, IFN-inducible 
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Fig. 1. (a) Multiple erythematous and encrusted ulcerations on the face 
following carbon dioxide laser therapy, and (b) several tender erythematous 
subcutaneous nodules on the forearm and a bulla on the base of the thumb.
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protein-10, monokine induced by INF-γ, and interferon 
inducible T-cell chemoattractant (ITAC), and adhesion 
molecules, including intercellular adhesion molecule-1 
and vascular cellular adhesion molecule-1 compared 
with normal controls. This immune response ultimately 
leads to an exaggerated lymphoit-helper (Th)1-type 
response and clinically induces papules and pustules 
on an erythematous base. 
The glycolytic enzyme α-enolase is typically located 
in the cytoplasm, but can be expressed in the cell mem-
branes of eukaryotic cells, including monocytes, T cells, 
B cells, neuronal cells, and endothelial cells, following 
an inflammatory stimulus through unknown mechanisms 
(2, 11, 12). Testing for antibodies to α-enolase has been 
proposed as a diagnostic tool or a biological marker for 
various conditions, including BD, Kawasaki’s disease, 
rheumatoid arthritis, and severe asthma (2, 11, 12). In 
the present case, we identified serum reactivity against 
human α-enolase as well as expressions of α-enolase 
in the cytoplasm of lymphohistiocytes, neutrophils, and 
endothelial cells from the biopsy specimen, demonstra-
ting the histological findings of erythema nodosum. 
According to a previous report (2), serum anti-α-enolase 
antibodies in BD can be associated with vascular system 
involvement. However, the association between serum 
anti-α-enolase antibodies and the risk of developing 
pathergy reaction has not been proven.
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Fig. 2. (a–b) Biopsy specimen obtained from 
the skin lesions on the forearm demonstrating 
septal infiltration of lymphohistiocytes and 
neutrophils with vasculitis consistent with the 
findings of erythema nodosum (haematoxylin 
and eosin stain, original magnification, a; ×100, 
b; ×400). (c–d) Immunohistochemistry of a 
biopsy section with rabbit anti-human α-enolase 
antibody showing expression of α-enolase in the 
cytoplasm of lymphohistiocytes, neutrophils, 
and endothelial cells (original magnification, 
c; ×100, d; ×400).
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